Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence of BDA MDI HFO vs BDA MDI HFA in Adults with Asthma
ChiCTR2600127842Phase 3Completed
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salbutamol + budesonide in asthma (3 arms), sponsored by Shanghai General Hospital. Primary endpoint: Change in peak FEV1 from baseline on Day 29 (0–60 minutes post-dose). Started Jul 2026; status: completed.
02
Drugs
salbutamol + budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2600127842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127842.